Role and potential of adipose-derived stem cells in cranio-maxillofacial bone regeneration / 中国组织工程研究

ABSTRACT

BACKGROUND: The repair of cranio-maxillofacial bone defects is still facing severe challenges, and the introduction of the concept of bone regeneration points out a new direction for this problem. Adipose-derived stem cells are easy to access and have strong osteogenic differentiation capacity, which are considered as ideal seed cells for cranio-maxillofacial bone regeneration. OBJECTIVE: To review the influencing factors of osteogenic differentiation of adipose-derived stem cells as well as the research progress in cranio-maxillofacial bone regeneration, thus providing ideas for further study on adipose-derived stem cells in promoting cranio-maxillofacial bone regeneration. METHODS: A computer-based online search of PubMed, Wanfang, and CNKI databases was performed to retrieve papers published from January 2013 to February 2020 with the search terms of “adipose-derived stem cells, cranio-maxillofacial, oral tissue regeneration, periodontal tissue regeneration, bone regeneration, bone defects, osteogenesis” in English and Chinese. Finally, 88 papers were included for summary. RESULTS AND CONCLUSION: Adipose-derived stem cells can be induced to differentiate to osteoblasts and are easy to acquire in large quantities. It has a strong ability of expansion in vitro and has a broad application prospect in the field of cranio-maxillofacial bone regeneration. miRNAs/microRNAs play a role in the osteogenic differentiation of adipose-derived stem cells. The osteogenic differentiation ability of adipose-derived stem cells can be improved by the means of co-culture with other cells, combined with platelet-rich plasma or modified titanium and gene technology. Compared with conventional extracorporeal scaffolds, adipose-derived stem cells combined with injectable scaffolds have greater potential in osteogenesis. Some progress has been made in repairing cranio-maxillofacial bone defects with adipose-derived stem cells, but there is still a lack of sufficient evidence in large-scale clinical trials.